Biogen Inc.(BIIB)
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Latest News & Analysis
Biogen Inc. Growth Strategy and Financial Analysis: Navigating MS Decline with ZURZUVAE, LEQEMBI & Manufacturing Expansion
Biogen pivots from MS decline, leveraging ZURZUVAE, LEQEMBI, and a $2B manufacturing boost to sustain growth and diversify its biotech portfolio.
Biogen Inc. Market Update: Navigating MS Challenges with Alzheimer's Pipeline Growth
Biogen faces MS sales decline while leveraging Alzheimer's drug momentum and manufacturing expansion to shape its financial future.
Biogen Inc. Strategic Pipeline Expansion and Financial Resilience Analysis - Monexa AI
Biogen pivots with late-stage pipeline advances in neurology, immunology, and rare diseases, supported by robust financials and strategic collaborations.
Biogen Inc. Market Update: Pipeline Advances and Financial Dynamics Shape BIIB's Future
Biogen's late-stage pipeline advances, strategic partnerships, and solid financial metrics highlight its growth potential amid evolving neurodegenerative and rare disease markets.
Biogen Inc. (BIIB) Strategic Pipeline Expansion and Financial Analysis
Biogen's strategic pipeline diversification into rare neurological diseases and immunology underpins recent financial performance and growth prospects.
Biogen Inc. Strategic Pipeline Expansion and Financial Overview | Biogen BIIB Analysis
Biogen advances late-stage pipeline with therapies like Zorevunersen and Felzartamab, showing strong R&D focus amid stable financials and strategic diversification.
Biogen Inc. Strategic Pipeline Diversification & Financial Performance Update | Monexa AI
Biogen pivots beyond CNS with felzartamab & SMA advances, showing solid financials and strategic growth in rare diseases and immunology.
Biogen Inc. Strategic Pivot and Financial Update: Immunology and Rare Diseases Drive Growth | Monexa AI
Biogen's strategic diversification into immunology and rare diseases, financial resilience, and pipeline advancements signal a transformative growth phase.
Biogen Inc. (BIIB) Market Analysis: Pipeline Progress and Financial Strength in Neuroscience
Biogen advances key neurology and immunology drug trials, showing robust R&D focus and improved financial health, setting a foundation for future growth.
Biogen Inc. Market Analysis: Earnings Surge and Strategic Financial Positioning
Biogen Inc. reports a +3.87% stock rise with robust earnings growth and strategic capital allocation, reshaping its competitive stance in biotech.
Biogen Inc. (BIIB) Latest Developments and Financial Insights for Strategic Investors
Comprehensive analysis of Biogen Inc.'s recent financial performance, strategic developments, and market positioning based on 2025 data.
Biogen (BIIB) Salanersen: SMA Strategy & Financial Analysis
Biogen's strategic advancements in SMA with salanersen (BIIB115) redefine its market position and financial trajectory.
Biogen (BIIB): Breakthrough SLE Data & Strategic Collaborations
Biogen's dapirolizumab pegol shows promising Phase 3 SLE results, signaling a potential breakthrough in autoimmune treatments. Strategic collaborations and robust financials underscore its market position.
Biogen's Strategic Evolution: Pipeline Catalysts & Financial Resilience
Biogen's latest advancements in clinical trials, strategic collaborations, and financial performance underscore its transformative journey in neuroscience and immunology.
Biogen Inc. (BIIB): Strategic Pivot and Financial Resilience Analysis
Analyzing Biogen Inc.'s latest strategic pivot towards RNAi and Alzheimer's, its recent financial performance showing net income growth despite revenue pressure, and the impact of evolving US drug pricing policies.
Biogen: Alzheimer's Drug, Acquisition Strategy, and Pipeline Challenges
Biogen faces challenges in MS drug sales but sees potential in Alzheimer's treatment and strategic diversification. Key developments and market analysis.
Biogen (BIIB) Analysis: Leqembi, MS Drug Sales, and Financials
Biogen navigates strategic shifts with new HQ, Leqembi's Alzheimer's potential, and efforts to offset MS drug sales decline. Financial health and R&D are key.
Biogen (BIIB): Felzartamab, Stoke, and Growth Beyond MS
Biogen faces MS drug sales decline but seeks growth via pipeline diversification and strategic collaborations. Felzartamab, Leqembi, and Stoke partnership are key.
Biogen (BIIB): Strategic Shifts, Pipeline Developments, and Financial Outlook
Biogen (BIIB) is strategically shifting towards rare diseases, leveraging collaborations, and enhancing R&D efficiency, impacting its market position and financial outlook.
Biogen (BIIB) Stock Analysis: Pipeline Progress, Market Challenges, and Investment Outlook
Biogen (BIIB) faces challenges but strategic initiatives offer potential growth. Valuation suggests it may be undervalued, presenting a potential opportunity for investors.
Biogen's Strategic Pivot: Leqembi, Rare Diseases, and Financial Restructuring
Biogen navigates market shifts with Leqembi, rare disease focus, and financial restructuring. Analysts eye growth strategy amid stock fluctuations.
Biogen (BIIB): Leqembi, Stoke Collaboration, and Analyst Outlook
Biogen (BIIB) navigates a complex landscape with Leqembi's market uptake, strategic collaborations, and analyst outlook, influencing investment decisions and market positioning.
Biogen (BIIB): Navigating Market Challenges and Pipeline Opportunities
Analysis of Biogen's latest developments: Q4 2024 earnings, Leqembi's market performance, Zorevunersen collaboration, MS franchise challenges, and strategic initiatives.
Biogen (BIIB): Earnings, Leqembi, and the Path to Recovery
Biogen (BIIB) navigates a complex landscape of declining franchises, Leqembi's challenges, and strategic shifts. Collaborations and cost-cutting are key, but analyst sentiment is cautious.
Biogen's Strategic Shift: Navigating Challenges and Embracing New Opportunities
An in-depth analysis of Biogen's Q4 2024 performance, strategic partnerships, and market repositioning amid evolving industry challenges.
Biogen's Dravet Syndrome Deal: Zorevunersen’s Pipeline Strategy
An in-depth analysis of Biogen’s collaboration on Zorevunersen for Dravet Syndrome, Q4 earnings, and strategic pipeline developments.